CONTACT

Connect With
Corporate Development

We welcome inquiries from investors, research partners, oncology professionals, and the media. Our corporate development team responds within one business day.

CORPORATE DEVELOPMENT

Get in Touch

We welcome inquiries from investors, research partners, oncology professionals, and the media. Our corporate development team responds within one business day.

CORPORATE DEVELOPMENT

Tibor Gajdics

President & CEO, Founding Director

HEADQUARTERS

Vancouver, British Columbia, Canada

LOCATIONS & OPERATIONS

HEADQUARTERS

Vancouver, British Columbia, Canada

SECONDARY OFFICE

Montreal, Quebec, Canada

CRO OPERATIONS

Montreal, Quebec, Canada (Galenvs Sciences)

RESEARCH COLLABORATION

Philadelphia, PA, USA (Thomas Jefferson University)

RESPONSE TIME

Within one business day

KOP Therapeutics

Advancing tumor-targeted RNA therapeutics toward IND-enabling development, partnership, and commercialization.

Preclinical Stage

DISCLAIMER

The information contained in this presentation is in summary form only, is not intended to be complete and may contain inadvertent or unintentional errors. No representation, warranty or guarantee, expressed or implied, is made as to the fairness, accuracy or completeness of information contained herein, including the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, results or statements in relation to future matters contained in this presentation. This presentation does not constitute an offer to sell or the solicitation of an offer to buy any security and is not intended to be relied upon as advice to investors or potential investors. KOP is not liable to any recipient or third party for the use of or reliance on the information contained in this presentation.

This communication contains forward-looking statements, which relate to future events or future performance, that are neither promises nor guarantees and are subject to numerous risks and uncertainties that may cause future results to differ materially from those expected and does not constitute an offer to sell or a solicitation of an offer to buy any securities. KOP's securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "1933 Act"), or any state securities laws and may not be offered or sold within the United States or to or for the account or benefit of a U.S. person (as defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws or an exemption from such registration is available.

Also, this communication is intended for the sole use of the addressee(s) and may contain confidential, personal and/or privileged information. Unless you are the intended recipient, we ask that you do not retain, disclose, distribute, or take action relying on any information contained herein, and that you please alert us immediately of the erroneous delivery by return e-mail. Any communication received in error, or subsequent reply should be deleted or destroyed. Thank you for your cooperation.

COPYRIGHT AND TRADEMARK

The information in this presentation (including certain names, graphics, logos, icons, designs, words, titles or phrases) is protected by copyright and other laws and may not be copied, reproduced, modified, uploaded, posted, transmitted, or distributed in any way without KOP's prior written approval. Any unauthorized downloading, re-transmission, re-publication or other copying or modification of trademarks and/or the contents herein is strictly prohibited.

© 2026 KOP Therapeutics Inc. All rights reserved.

Montreal, Quebec, Canada · 604.256.9900